Guillaume Becker

1.5k total citations
19 papers, 227 citations indexed

About

Guillaume Becker is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Guillaume Becker has authored 19 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Guillaume Becker's work include Chronic Lymphocytic Leukemia Research (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Guillaume Becker is often cited by papers focused on Chronic Lymphocytic Leukemia Research (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Guillaume Becker collaborates with scholars based in France, Canada and Czechia. Guillaume Becker's co-authors include Dominique Levêque, Shanti Natarajan‐Amé, Karin Bilger, Catherine Paillard, Luc‐Matthieu Fornecker, Elise Toussaint, B. Gourieux, Véronique Kemmel, Geneviève Ubeaud-Séquier and Bruno Michel and has published in prestigious journals such as PLoS ONE, International Journal of Pharmaceutics and Food and Chemical Toxicology.

In The Last Decade

Guillaume Becker

18 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guillaume Becker France	8	68	49	44	35	24	19	227
Michelle Teodoro Alves Brazil	11	55 0.8×	36 0.7×	56 1.3×	30 0.9×	27 1.1×	22	300
Sonu Gupta India	9	93 1.4×	89 1.8×	56 1.3×	32 0.9×	18 0.8×	37	361
Zahra Talebi United States	8	63 0.9×	87 1.8×	34 0.8×	18 0.5×	9 0.4×	29	232
E. Baumelou France	8	59 0.9×	74 1.5×	63 1.4×	23 0.7×	39 1.6×	18	521
Xin Tian China	10	69 1.0×	24 0.5×	27 0.6×	30 0.9×	6 0.3×	34	246
Slavica Milosavljev Switzerland	8	51 0.8×	46 0.9×	74 1.7×	53 1.5×	11 0.5×	10	335
Selina Moy United States	9	55 0.8×	49 1.0×	37 0.8×	24 0.7×	6 0.3×	16	383
Cataldo Doria United States	14	71 1.0×	39 0.8×	19 0.4×	11 0.3×	30 1.3×	35	407
Silvana Anna Maria Urru Italy	10	86 1.3×	75 1.5×	23 0.5×	32 0.9×	39 1.6×	23	328

Countries citing papers authored by Guillaume Becker

Since Specialization

Citations

This map shows the geographic impact of Guillaume Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillaume Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillaume Becker more than expected).

Fields of papers citing papers by Guillaume Becker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillaume Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillaume Becker. The network helps show where Guillaume Becker may publish in the future.

Co-authorship network of co-authors of Guillaume Becker

This figure shows the co-authorship network connecting the top 25 collaborators of Guillaume Becker. A scholar is included among the top collaborators of Guillaume Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillaume Becker. Guillaume Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kawka, Lou, et al.. (2024). The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials. Autoimmunity Reviews. 23(7-8). 103590–103590. 4 indexed citations

Becker, Guillaume, et al.. (2023). Flavoured and nicotine-containing e-liquids impair homeostatic properties of an alveolar-capillary cell model. Food and Chemical Toxicology. 174. 113650–113650.

Arnaud, Laurent, et al.. (2023). The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. 9(3). e003279–e003279. 11 indexed citations

Collongues, Nicolas, Guillaume Becker, Valérie Jolivel, et al.. (2022). A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. Neurology and Therapy. 11(3). 981–1042. 12 indexed citations

Becker, Guillaume, et al.. (2021). The 5-hydroxytryptamine receptor type 4 regulates blood-brain-barrier permeability. Archives of Cardiovascular Diseases Supplements. 13(2). 184–184. 1 indexed citations

Becker, Guillaume, et al.. (2021). Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?. Pharmaceutics. 13(11). 1856–1856. 5 indexed citations

Becker, Guillaume, et al.. (2021). Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology. Pharmaceutics. 13(4). 470–470. 10 indexed citations

Becker, Guillaume, Thierry Martin, F. Bertrand, et al.. (2021). Impact of the COVID-19 pandemic on clinical research in hospitals: observational study in the first epicenter of the epidemic during the general lockdown in France.. PubMed. 25(2). 1158–1162. 2 indexed citations

Ayme‐Dietrich, Estelle, et al.. (2021). Characterization of the spontaneous degenerative mitral valve disease in FVB mice. PLoS ONE. 16(9). e0257022–e0257022. 4 indexed citations

10.

Becker, Guillaume, et al.. (2021). Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review. Current Medical Research and Opinion. 37(11). 1855–1858. 1 indexed citations

11.

Levêque, Dominique, Guillaume Becker, Karin Bilger, & Shanti Natarajan‐Amé. (2020). Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clinical Pharmacokinetics. 59(7). 849–856. 67 indexed citations

12.

Javelot, Hervé, et al.. (2020). COVID‐19 and (hydroxy)chloroquine–azithromycin combination: Should we take the risk for our patients?. British Journal of Clinical Pharmacology. 86(6). 1176–1177. 18 indexed citations

13.

Levêque, Dominique & Guillaume Becker. (2019). The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics. Expert Opinion on Drug Safety. 18(11). 1009–1015. 20 indexed citations

14.

Nazon, Charlotte, et al.. (2019). Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach. Journal of Clinical Medicine. 8(10). 1701–1701. 6 indexed citations

15.

Levêque, Dominique, Guillaume Becker, Elise Toussaint, Luc‐Matthieu Fornecker, & Catherine Paillard. (2017). Clinical Pharmacokinetics of Methotrexate in Oncology. 2(2). 137–147. 30 indexed citations

16.

Cordeau, Jean‐François, et al.. (2017). Optimisation du parcours patient en Hôpital de Jour en oncohématologie par simulation intégrée à une démarche kaizen*. Logistique & Management. 25(1). 34–42. 5 indexed citations

17.

Beck, M., et al.. (2016). A UV-Raman spectrometry method for quality control of anticancer preparations: Results after 18 months of implementation in hospital pharmacy. International Journal of Pharmaceutics. 499(1-2). 343–350. 25 indexed citations

18.

Levêque, Dominique, et al.. (2015). Mécanismes des interactions pharmacocinétiques impliquant les agents anticancéreux oraux. Bulletin du Cancer. 102(1). 65–72. 4 indexed citations

19.

Becker, Guillaume, et al.. (1951). [Histologic modifications of the frog's skin produced by ultrasonic waves and other physical agents as seen in studies of capillary permeability].. PubMed. 84(2). 306–13. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact